Sama Therapeutics
Shobi A. is the Founder and Chief Executive Officer of Sama Therapeutics since January 2022. Prior experience includes serving as a Consultant in Clinical Pipeline R&D at Biohaven Pharmaceuticals, Director of Clinical & Scientific Operations at Transcend Therapeutics, and Venture Fellow at AlleyCorp. Additionally, Shobi held roles as a Consultant for Program Development at Curebase and Principal Clinical Investigator at nference. Earlier experience includes directing R&D at Amelio and conducting doctoral research at Harvard University. Shobi's educational background includes an MD from Yale School of Medicine, a PhD and MA from Harvard University in Near Eastern Languages & Civilizations, and a BS/BA in Biomedical Engineering and the History of Science, Medicine & Philosophy from The Johns Hopkins University.
This person is not in any teams
Sama Therapeutics
1 followers
Sama Therapeutics is a precision neuropsychiatry AI/ML platform that synthesizes and validates predictive biomarkers grounded in neural, physiological, multi-omics, natural language, and behavioral phenotypes. The company's agile SaaS platform, iMAGiNE™, analyzes the transdiagnostic efficacy of pharmaceutical and neurostimulation modalities through precision clinical trials, causal inference, preclinical translation, and generative AI trained on proprietary and open-science datasets. With an extraordinarily interdisciplinary team, Sama Therapeutics is advancing "software as medical device" for a range of indications, including cognitive, affective, interoceptive, and substance use disorders. We invite partners to join our mission unlocking brain health through integrative neurotechnology and proven “transprognostic” algorithms: https://brainclinics.com/tdbrain-challenge/ Please reach out to contact@sama.ac for more information and a live demo.